Market Overview:Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma affecting B-cells. It accounts for around 30% of non-Hodgkin lymphomas in adults. Standard treatment involves chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. However, about 30-40% of patients either relapse or are refractory to initial therapy. Market...
0 Commentarios
0 Acciones
858 Views
0 Vista previa
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian